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Abstract
Background: A recently discovered occult HCV entity reported by various investigators seems to be highly
controversial. Especially, the clinical significance of these findings remains uncertain. For optimal outcome of
antiviral therapy, investigation of occult HCV needs a broad-based probe in order to investigate the results of viral
therapy and its host/viral interaction. The current study was aimed at determining the prevalence of occult HCV in
peripheral blood lymphocytes of predominantly genotype 3 HCV-infected patients after completion of antiviral
therapy and to investigate long term outcomes in the presence or absence of PBMC positivity.
Method: A total of 151 chronic, antiHCV and serum RNA-positive patients were enrolled in the study. Patients with
a complete virological response at the end of treatment were screened for the presence of viral RNA in their
PBMCs and were followed for up to one year for the presence of serum and PBMC viral genomic RNA.
Results: Out of 151 patients, 104 (70%) responded to the prescribed interferon treatment and showed viral-
clearance from serum. These were screened for the presence of genomic RNA in their PBMCs. Sixteen samples
were PBMC-positive for viral RNA at the end of treatment (EOT). All these patients had also cleared the virus from
peripheral blood cells after the 6-12 month follow-up study.
Conclusion: True occult hepatitis C virus does not exist in our cohort. Residual viremia at the EOT stage merely
reflects a difference in viral kinetics in various compartments that remains a target of immune response even after
the end of antiviral therapy and is eventually cleared out at the sustained viral response (SVR).
Introduction
Hepatitis C is the leading cause of liver disease infecting
about 200 million individuals worldwide. HCV is a single-
stranded virus of the flaviviridae family that replicates by
its negative strand. In most cases of infection (85%) the
virus evades the immune system and establishes a chronic
infection that may lead to cirrhosis and liver carcinoma
[1,2]. The hallmarks of chronic infection are antiHCV
positivity, presence of genomic HCV RNA in the serum
for more than six months and abnormal liver function
tests. Current treatment standards with pegylated inter-
feron alpha (PEG IFN-alpha) and ribavirin in genotype 1
and PEG/Standard Interferon with Ribavirin in genotype
2,3 result in sustained response rates of 50% and 76-80%
respectively [2,3]. In addition to the large number of non-
responding patients the treatment has further limitations
due to its toxicity and high cost, especially for patients in
the developing world. Moreover, recent data suggest that
response rates in genotype 3 are not as optimal as pre-
viously believed with relapse rates up to 40% resulting in a
growing pool of patients who fail to clear the virus [4].
Attempts to improve response rates have focused on pre-
treatment and treatment predictors like viral kinetics in an
attempt to optimize treatment duration and improve sus-
tained outcome. Eradication of the virus is judged by the
absence of viral RNA from the serum with normalization
of liver function tests. PCR-based methods that can detect
very low levels of viral genome have given a new
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toring of the later consequences of the disease.
Occult HCV infection, a recently identified type of
HCV infection that is still controversial is defined as the
persistent presence of detectable HCV RNA in hepato-
cytes or peripheral blood mononuclear cells (PBMCs) of
patients with undetectable plasma HCV-RNA by conven-
tional PCR assays [5,6]. It is thought that the presence of
occult-HCV may be indicated by abnormal liver function
tests or antiHCV positivity although the virus may persist
for years after spontaneous recovery or after sustained
viral response (SVR) [6]. Hepatic cells are the primary
targets of the virus. Occult is usually more established in
hepatocytes but lymphocytes have also been found to
serve as a ‘hideout’. Some investigators have also reported
t h ep r e s e n c eo fi n t e r m e d i a t en e g a t i v es t r a n d si nt h e
PBMC, thereby indicating active viral replication and per-
sistence in PBMCs. The identification of occult was made
possible due to the higher sensitivity of PCR-based meth-
ods [7-9]. It is believed that the immune system and liver
tissue act as reservoirs of this kind of infection resulting
in relapse and potential return to overt infectious state.
In addition, it is believed that occult RNA can lead to
persistent minimal inflammation or even chronic active
hepatitis. Occult hepatitis C is considered a milder dis-
ease than chronic hepatitis C but little is known about
clinical history, progression or outcomes [5]. Occult
HCV infection has also been identified in chronic hepati-
tis C patients who have responded to antiviral therapy
with sero-clearance and normalization of liver functions.
This finding therefore challenges the belief that serum
HCV resolution reflects complete viral eradication.
In Pakistan, there are approximately 10 million people
living with hepatitis C infection [10]. Current study was
undertaken in order to determine the prevalence of
occult HCV among predominantly geno 3-infected
chronic hepatitis C patients responding to antiviral ther-
apy and to analyze its effect on the final outcomes. Due
to higher cost, PEG interferon is given as second line
therapy only to patients who do not respond to Standard
Interferon Therapy (SIT). Liver biopsy samples are con-
sidered the gold standard for occult HCV RNA detection,
but performing such invasive procedure is considered
unethical, especially in the absence of any clinical presen-
tation. Because PBMC analyses have proved to be equally
useful for this purpose, we therefore opted for the nonin-
vasive PBMC analyses in order to determine the presence
occult HCV in our cohort [9]. The cohort consisted of
patients who had attained a complete end-treatment
response. In order to detect the occult phase at an early
stage we assumed that PBMC positivity at EOT might
reflect a higher prevalence of the occult HCV. The study
is an effort to add information to the complex natural
history of HCV disease which shows interplay of the
host, virus and the environment.
Materials and methods
The patient cohort included nonalcoholic, chronic liver
disease patients from the Dept. of Medicine, KRL
General Hospital, Islamabad, Pakistan. Most patients
were residents of the Potohar region who visited the hos-
pital during 2007-2009 and who reached the EOT stage
of antiviral therapy. Exclusion criteria were immunocom-
promised patients including pregnant women, HIV-posi-
tive patients, patients on steroids and patients who were
HBV-positive or positive for any other viral infections.
The study was conducted according to ethical guide lines
of the 2000 Helsinki Declaration, and duly approved by
the ethical committee of the institute. Patients gave writ-
ten informed consent for their participation in the study.
Plan of the study is summarized in Figure 1, briefly,
blood samples of the patients (151) were collected at the
end of treatment (EOT) and serum was screened for viral
RNA. Serum-negative patients were selected (104) and
their PBMCs isolated subsequently. The patients were
divided into two groups. The first group consisted of
treatment-naïve patients (n = 87) who were administered
Standard Interferon Therapy with Ribavirin for 72 weeks
a n dt h es e c o n dg r o u p( n=1 7 )i n c l u d e dt r e a t m e n t -
experienced patients who were administered PEG inter-
feron with Ribavirin for 24 weeks as the second line of
Figure 1 Study design.
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ment in this region due to the high cost of PEG inter-
feron which is administered only as second line therapy
to the approximately 30% patients who remain non SVR
[11]. Table 1 shows the base-line parameters of the
patients. Same patients were followed at SVR (6-12
months) and their PBMCs isolated again and analyzed
for the presence of genomic HCV RNA.
HCV-RNA detection
HCV RNA was detected by using a commercially available
RT-PCR kit COBAS AMPLICOR Hepatitis C virus test
ver 2.0 (Roche Molecular Diagnostics, Mannheim, Ger-
many) with a sensitivity limit of 50 IU/ml and 99% specifi-
city. Briefly, viral RNA was extracted from plasma by lysis
of viral particles with guanidinium thiocyanate (chaotropic
agent), followed by alcohol precipitation. HCV RNA was
retrotranscribed to cDNA and amplified by the single tube
RT-PCR primer set, KY78 (5’-CTCGCAAGCACCCTAT-
CAGGCAGT-3’)a n dK Y 8 0( 5 ’-GCAGAAAGCGTC-
TAGCCATGGCGT-3’) ,t oa m p l i f yas e q u e n c eo f2 4 4
nucleotides within the conserved 5’UTR of the HCV gen-
ome. Amplified DNA was detected using target-specific
oligonucleotide probes that permitted independent identi-
fication of HCV amplicons and internal control amplicons.
Isolation of serum and PBMC
Serum was separated from whole blood in vacutainers
containing serum enhancer following centrifugation.
Isolated serum was immediately stored at -20°C in
appropriate aliquots in order to avoid repeat freeze-
thawing. Peripheral blood lymphocytes were isolated
immediately following blood drawing (5.0 ml) from
serum-negative patients. Whole blood was layered over
Ficoll-Hypaque (Sigma, USA) density- gradient medium.
Cells were isolated from the buffy coat after centrifuga-
tion and were washed three times with phosphate buf-
fered saline (pH 7.0). The cells were observed under
inverted microscope and counted using a haemacyt-
ometer. Aliquots of approximately a million cells sus-
pended in RNAse-free dd H2O were then preserved at
-70°C to avoid repeat freeze/thawing. HCV RNA was
analyzed from cell lysates using the Roche Amplicor kit.
Two positive control samples from the blood of serum
positive patients were processed along with the batch of
test samples.
Statistical analyses
Analyses of base line parameters with PBMC-positive
and -negative patients were performed using SPSS ver
10.0 for windows (SPSS, Inc; Chicago, IL, USA).
Results
One hundred and fifty one patients were evaluated after
the end of prescribed antiviral therapy. Out of these, 104
patients (70%) showed treatment response by clearing
the virus from the serum, while 47 patients were either
relapsers or non-responders to the prescribed therapy at
the end of treatment. From the responders, 87 were
treatment-naïve and 17 were treatment experienced
patients. All the responders were tested for the presence
of virus in their peripheral blood mononucleocytes. Six-
teen patients (15.8%) were found positive for the viral
RNA, 11 from the naïve and 5 from the treatment-experi-
enced patients (Table 2). These patients were considered
occult and we applied the 2 × 2 contingency chi-square
test to determine if there was any association with occult
HCV in the two groups of patients, i.e treatment-naïve
and treatment-experienced. No significant association
was found (Pearson chi square = 0.08). We also applied
the chi square as well as one way ANOVA to work out
association between all the basic parameters listed in
T a b l e1f o rb o t hg r o u p so fp a t i e n t sa n dd i dn o tf i n da n y
significant associations. All these patients were followed
up for SVR and their PBMC were analyzed at the SVR
stage as well. All patients who showed positivity at the
end of treatment, cleared the virus at the SVR stage. We
also observed one lymphocyte sample that remained
slightly positive after 6 months but cleared the virus
completely by 12 months post-EOT.
Table 1 Patients baseline parameters
Group 1 Group 2
Naive(n = 87) Experienced(n = 17)
Gender (Male:Female) 30:57 3:14
Age (mean ± SD) 42.9 ± 10.6 47.29 ± 8.92
ALTs (IU/ml ± SD) 74.8 ± 60.1 94.1 ± 78.8
BMI (± SD) 23.88 ± 6.6 24.64 ± 5.2
Cholesterol (± SD) 181.42 ± 38.2 188.07 ± 22.9
Triglycerides (± SD) 177.16 ± 53.22 170.15 ± 50.03
Base line Quant (range) 1×1 0
3-5.8 × 10
6 1×1 0
3-2 × 10
6
LDL (normal/high) 58/4 13/0
HDL(normal/high) 58/4 13/0
Inflammation
A1 38 (.43) 9 (.53)
A2 5 (.057) 1 (.058)
A3 15 (.17) 5 (.294)
Not done 29 (.33) 2 (.11)
Fibrosis
F0 45(.52) 10(.59)
F1 13(.15) 3(.17)
F2 5(.005) 1(.005)
F3 1(.001) 0
Not done 23(.26) 3(.17)
A1, A2, A3 are mild, moderate and marked inflammation respectively.
F0, F1, F2, F3 are no, mild, moderate and marked fibrosis respectively.
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Occult HCV infection has been defined as the presence
of HCV RNA in liver and/or lymphoid cells despite
undetectable HCV-RNA in the serum in HCV-infected
patients who have a spontaneous clearance or antiviral
treatment response. The current study was primarily
aimed at determining the prevalence of occult HCV in
predominantly 3(a/b)-infected HCV patients and sec-
ondly to investigate if PBMC positivity can be seen as
an indicative marker for later recurrence of viral parti-
cles in the serum. Our cohort was infected with the sub-
type of occult HCV defined by the presence of HCV
RNA in PBMCs of patients with treatment-induced
HCV RNA clearance from serum (antiHCV- positive,
serum HCV RNA-negative). It should also be mentioned
that the sample collection was random for the genotype
selection, but the cohort turned out to be 100% geno-
type 3, which has already been reported as the predomi-
nant type of HCV in Pakistan, especially in the Potohar
region [11,12]. This also reinforces our own previous
observation of genotype 3 as the most prevalent geno-
type in the region; therefore our conclusions are more
relevant for HCV genotype 3. Our study also shows a
70% success rate for the sustained response achieved
through interferon alpha/ribavirin combined therapy as
reported previously [2] for genotype 3.
Liver biopsy samples are considered the gold standard
for occult HCV diagnosis; but due to the invasive nature
of this method, especially in the absence of clinical man-
ifestations, reliable alternative methods of investigation
have also been developed [7]. HCV RNA has been
reported in PBMC as well as ultracentrifuged serum
samples in a high percentage of patients (70%) and is
considered a reliable method for occult detection as
repeat liver biopsy samples are not usually available in
clinical practice [13]. We therefore, relied on the HCV
detection in lymphocytes for our method of investiga-
tion. According to the current definition of occult as
serum-clear, treated patients, we considered the pre-
sence of positive PBMCs in the end-of-treatment speci-
mens as evidence of occult HCV. Our results showed
viral genomic HCV present in the PBMCs of 15.8% of 3
(a/b) chronically infected HCV patients at EOT. The fol-
low up studies, however, showed that the HCV particles
that are present in the PBMC of the patients at the end
of treatment are ultimately cleared out by 6-12 months
after EOT at the SVR stage. We did not find any asso-
ciation of delayed clearance with any of the baseline
parameters listed in Table 1 as previously reported
[14,15]. The SVR stage results therefore lead us to con-
clude that the 15.8% EOT viral presence reflects a differ-
ence in the viral kinetics in various compartments rather
than a true case of occult HCV. It is also worth men-
tioning that there has been a recent report on the study
of occult virus in the region; but the cohort consisted of
non-treated cryptogenic virus-infected patients who
were antiHCV-negative and showed increased ALT (ala-
nine amino transferase) and AST (aspartate amino
transferase) levels [16]. These results may reflect a true
case of occult HCV. Our results also indicate the
Table 2 Baseline parameters of all patients who were serum negative, PBMC positive at the EOT stage
Ser No. Gender Age yrs ALT cholest HDL LDL T4 Treat Quant x10
6 Inflm Fibr
1 M 35 NA NA NA NA NA SIT .56 3 3
2 M 55 18 NA NA NA NA SIT 1 3 2
3 F 34 71 90 40 102 178 SIT .13 1 1
4 M 48 93 178 30 129 188 SIT .006 3 0
5 F 32 78 199 38 96 179 SIT .046 1 0
6 F 39 87 207 37 125 273 SIT .001 1 0
7 F 49 76 160 42 98 180 SIT 1 NA 0
8 F 40 19 200 36 98 120 SIT 1 1 0
9 M 60 88 180 42 90 78 SIT .0063 3 2
10 F 52 50 236 32 90 140 SIT 1 1 0
11 F 44 60 139 36 96 144 SIT NA 1 0
12 F 37 96 190 36 107 220 SIT
r 1.81 1 1
13 F 36 19 139 40 75 140 SIT
r .3 1 0
14 F 62 62 201 34 102 178 SIT
r .04 1 0
15 F 49 46 NA NA NA NA SIT
r .0127 NA NA
16 F 51 112 198 32 86 120 SIT
nr 2.13 3 0
SIT
r relapse to SIT.
SIT
nr nonresponder to SIT.
NA not available.
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even after the completion of the treatment regimen and
that it helps in clearing of the residual virions that
might remain detectable in other compartments.
It could be argued that lack of detection of HCV in the
PBMC of our cohort at SVR is due to low sensitivity of
our test (50 IU/ml), which may be too low to detect the
presence of very small amounts of occult viral particles;
but in our study plan we followed the same cohort of
patients who initially (EOT) showed the presence of
occult virus in their PBMC with the same sensitivity
level. It is also worth mentioning that one of the ‘occult’
samples, although still weakly positive at 6 months post
EOT, was observed to gradually clear the residual viremia
at one year post-treatment. However, we could not
exclude the possibility of viral persistence in the hepatic
cells in our cohort of patients as none of them presented
any indication for a liver biopsy test, such as raised ALTs
at the EOT. These patients will be periodically followed
up and liver biopsies carried out if needed. According to
our current findings we conclude that clinicians may be
confident of the clearance of the virus as indicated by the
absence of viral RNA in the serum at the EOT especially
i nt h ec a s eo fg e n o t y p e3i n f e c t i o n .Ap r e v i o u ss t u d yo n
five geno 3 patients also showed clearance of virus after
56 months of treatment [17].
The question remaining is why the virus is cleared later
from the PBMC than the serum (15.8% cases). This cannot
be explained clearly due to the incomplete understanding
of the HCV infection and evasion processes. It can be pro-
pounded, however, that HCV has developed a number of
evasion mechanisms, infection of PBMCs being one of
those where the virus can avoid the immune defense sys-
tem, while hepatocytes remain the actual target. We tried
to find an association of baseline viral load and other clini-
cal parameters with final clearance of virus, since some
researchers have shown an association of occult presence
with high cholesterol and triglyceride levels [14,15]. Statisti-
cal tests were applied to determine if there was an associa-
tion with any of the base line parameters given in Table 1,
but no such evidence was found. It may also be that the
virus developed some new quasi-species in PBMC that
showed delayed response to the antiviral therapy but we
could not confirm that speculation.
The outcome of therapy involves an interplay of host
and viral factors in their specific environments, which ulti-
mately determines the immune response at both the
innate and humoral response levels of the host. It is diffi-
cult, therefore, at this stage to determine the effect of clini-
cal and biochemical parameters as markers for disease
outcome. It would be worthwhile to study the known host
and viral genetic factors that might contribute to the
immune response in the patients and provide a better
understanding of the observed treatment responses. The
existence of occult HCV as a reservoir of the virus, that
can become active has remained controversial since its
first report in 2004 [5]. There have been recent negative
reports in other genotypes also [18-22]. Therefore, the pic-
ture is still unclear. Further detailed, long-term studies are
needed before clinicians can be confident that the serum
based tests are accurate.
Conclusion
In conclusion, the results of our study show differences in
viral kinetics in different compartments. Viral persistence
in the PBMC compartment at the EOT stage and its sub-
sequent clearance at the SVR stage shows delayed clear-
ance in the lymphoid cells as compared to plasma.
Persistence at the EOT stage is not an indicator of subse-
quent relapse by SVR stage.
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